A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
A comparison of fluoxetine and amitriptyline in the treatment of major depression.
Fluoxetine , a new serotonin uptake blocking antidepressant , was compared with amitriptyline in a double-blind study . Patients were diagnosed as having major depression , according to DSM-III criteria , when interviewed with the Diagnostic Interview Schedule . There was significant improvement in patient and observer ratings of depression in both groups , with no difference between groups . Recent memory improved significantly in the fluoxetine group but not in the amitriptyline group . Numbers of patients reporting side-effects were similar but the profiles of side-effects were different , with more patients on amitriptyline reporting anticholinergic and intolerable side-effects
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .